# Clinical Trials Data KRAS - Document 22

# Observational Study on Treatment of Metastatic Colorectal Cancer and the Role of K-Ras

## Clinical Trial: https://clinicaltrials.gov/study/NCT01651013

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Histologic diagnosis colorectal carcinoma\n\* Metastatic disease\n\* Signed informed consent\n\nExclusion Criteria:\n\n\* Prior treatment of metastatic colorectal cancer\n\* Refusal or incapability of providing informed consent",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
],  
 "studyPopulation": "Patients at participating Institutes who are candidate for first-line treatment of metastatic colorectal cancer",

Question:  
Based on the following clinical trial information, would a patient with a KRAS gene mutation be eligible for the clinical trial?

Answer:  
To determine if a patient with a KRAS gene mutation is eligible for this clinical trial, we need to review the provided eligibility criteria.   
  
\*\*Inclusion Criteria:\*\*  
- Histologic diagnosis of colorectal carcinoma  
- Metastatic disease  
- Signed informed consent  
  
\*\*Exclusion Criteria:\*\*  
- Prior treatment of metastatic colorectal cancer  
- Refusal or incapability of providing informed consent  
  
There is no mention of KRAS gene mutation status in either the inclusion or exclusion criteria. Therefore, a patient with a KRAS gene mutation would not be automatically excluded based on the mutation status and would appear to be eligible for this clinical trial, assuming they meet all the other inclusion criteria and none of the exclusion criteria besides the gene mutation aspect apply to them.